Drug intelligence / Profile preview

INV321

Development stage: Preclinical
Lead developer: Invenra
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

INV321 is a preclinical-stage multispecific antibody developed by Invenra using its proprietary SNIPER platform. It is designed to target and modulate or deplete regulatory T cells (Tregs) within the tumor microenvironment to enhance anti-tumor immunity. By selectively addressing Tregs, INV321 aims to overcome immune suppression and improve outcomes in solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer (NSCLC).

Beyond the preview

Go deeper on INV321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV321.

Explore the full profile